Handelsbanken Fonder AB Purchases 400 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Handelsbanken Fonder AB lifted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 5,672 shares of the medical research company’s stock after buying an additional 400 shares during the period. Handelsbanken Fonder AB’s holdings in Bio-Rad Laboratories were worth $1,863,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC increased its holdings in Bio-Rad Laboratories by 2,175.0% during the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after purchasing an additional 87 shares in the last quarter. Gladius Capital Management LP bought a new position in Bio-Rad Laboratories during the third quarter worth about $32,000. Asset Planning Inc acquired a new stake in Bio-Rad Laboratories during the fourth quarter worth approximately $33,000. UMB Bank n.a. lifted its position in Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after acquiring an additional 32 shares during the last quarter. Finally, Point72 Hong Kong Ltd acquired a new stake in Bio-Rad Laboratories during the third quarter worth approximately $55,000. Institutional investors own 65.24% of the company’s stock.

Wall Street Analysts Forecast Growth

BIO has been the subject of several research reports. Royal Bank of Canada restated an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Wells Fargo & Company lowered their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Finally, Citigroup boosted their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock opened at $277.81 on Wednesday. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a twelve month low of $262.12 and a twelve month high of $387.99. The stock has a market cap of $7.78 billion, a price-to-earnings ratio of -4.27 and a beta of 0.90. The company’s fifty day moving average is $330.43 and its 200 day moving average is $333.76.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.